Nurix Therapeutics Inc (NRIX)

$14.16

+0.94

(+7.11%)▲

Market is closed - opens 7 PM, 08 May 2024

Insights on Nurix Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 15.15M → 16.58M (in $), with an average increase of 8.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -41.95M → -41.51M (in $), with an average increase of 1.1% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 236.5% return, outperforming this stock by 283.9%

Performance

  • $13.18
    $14.35
    $14.16
    downward going graph

    6.92%

    Downside

    Day's Volatility :8.15%

    Upside

    1.32%

    downward going graph
  • $4.22
    $18.12
    $14.16
    downward going graph

    70.2%

    Downside

    52 Weeks Volatility :76.71%

    Upside

    21.85%

    downward going graph

Returns

PeriodNurix Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
64.27%
-1.1%
0.0%
6 Months
153.76%
11.2%
0.0%
1 Year
53.58%
7.0%
0.8%
3 Years
-45.89%
14.9%
-22.1%

Highlights

Market Capitalization
754.8M
Book Value
$3.43
Earnings Per Share (EPS)
-2.66
Wall Street Target Price
24.6
Profit Margin
-178.93%
Operating Margin TTM
-272.65%
Return On Assets TTM
-28.8%
Return On Equity TTM
-65.37%
Revenue TTM
80.9M
Revenue Per Share TTM
1.48
Quarterly Revenue Growth YOY
30.7%
Gross Profit TTM
-145.9M
EBITDA
-150.9M
Diluted Eps TTM
-2.66
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.91
EPS Estimate Next Year
-3.17
EPS Estimate Current Quarter
-0.8
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    89%Buy
    10%Hold
    0
    0%Sell
Based on 19 Wall street analysts offering stock ratings for Nurix Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 19 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
17
17
17
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 73.73%

Current $14.16
Target $24.60

Company Financials

FY18Y/Y Change
Revenue
37.4M
-
Net Income
-9.4M
-
Net Profit Margin
-25.18%
-
FY19Y/Y Change
Revenue
31.1M
↓ 16.91%
Net Income
-21.7M
↑ 130.15%
Net Profit Margin
-69.74%
↓ 44.56%
FY20Y/Y Change
Revenue
17.8M
↓ 42.73%
Net Income
-43.2M
↑ 99.28%
Net Profit Margin
-242.66%
↓ 172.92%
FY21Y/Y Change
Revenue
29.8M
↑ 66.95%
Net Income
-117.2M
↑ 171.02%
Net Profit Margin
-393.93%
↓ 151.27%
FY22Y/Y Change
Revenue
38.6M
↑ 29.84%
Net Income
-166.0M
↑ 41.68%
Net Profit Margin
-429.87%
↓ 35.94%
FY23Y/Y Change
Revenue
77.0M
↑ 99.31%
Net Income
-143.9M
↓ 13.31%
Net Profit Margin
-186.98%
↑ 242.89%
Q4 FY22Q/Q Change
Revenue
6.8M
↓ 37.14%
Net Income
-41.7M
↓ 6.7%
Net Profit Margin
-614.88%
↓ 200.65%
Q1 FY23Q/Q Change
Revenue
12.7M
↑ 87.01%
Net Income
-35.3M
↓ 15.28%
Net Profit Margin
-278.55%
↑ 336.33%
Q2 FY23Q/Q Change
Revenue
30.7M
↑ 141.83%
Net Income
-21.8M
↓ 38.33%
Net Profit Margin
-71.03%
↑ 207.52%
Q3 FY23Q/Q Change
Revenue
18.5M
↓ 39.8%
Net Income
-37.0M
↑ 69.73%
Net Profit Margin
-200.26%
↓ 129.23%
Q4 FY23Q/Q Change
Revenue
15.2M
↓ 17.91%
Net Income
-42.0M
↑ 13.45%
Net Profit Margin
-276.77%
↓ 76.51%
Q1 FY24Q/Q Change
Revenue
16.6M
↑ 9.41%
Net Income
-41.5M
↓ 1.04%
Net Profit Margin
-250.33%
↑ 26.44%
FY18Y/Y Change
Total Assets
45.4M
-
Total Liabilities
82.2M
-
FY19Y/Y Change
Total Assets
44.0M
↓ 2.97%
Total Liabilities
101.8M
↑ 23.73%
FY20Y/Y Change
Total Assets
396.3M
↑ 799.8%
Total Liabilities
106.1M
↑ 4.24%
FY21Y/Y Change
Total Assets
476.8M
↑ 20.29%
Total Liabilities
134.5M
↑ 26.77%
FY22Y/Y Change
Total Assets
416.8M
↓ 12.59%
Total Liabilities
113.1M
↓ 15.92%
FY23Y/Y Change
Total Assets
364.5M
↓ 12.53%
Total Liabilities
164.0M
↑ 45.09%
Q4 FY22Q/Q Change
Total Assets
416.8M
↓ 9.27%
Total Liabilities
113.1M
↓ 3.19%
Q1 FY23Q/Q Change
Total Assets
370.2M
↓ 11.18%
Total Liabilities
96.1M
↓ 15.0%
Q2 FY23Q/Q Change
Total Assets
350.6M
↓ 5.28%
Total Liabilities
90.7M
↓ 5.62%
Q3 FY23Q/Q Change
Total Assets
308.2M
↓ 12.1%
Total Liabilities
74.4M
↓ 18.0%
Q4 FY23Q/Q Change
Total Assets
364.5M
↑ 18.28%
Total Liabilities
164.0M
↑ 120.56%
Q1 FY24Q/Q Change
Total Assets
312.7M
↓ 14.23%
Total Liabilities
143.9M
↓ 12.26%
FY18Y/Y Change
Operating Cash Flow
-31.7M
-
Investing Cash Flow
40.0M
-
Financing Cash Flow
529.0K
-
FY19Y/Y Change
Operating Cash Flow
601.0K
↓ 101.9%
Investing Cash Flow
8.5M
↓ 78.75%
Financing Cash Flow
126.0K
↓ 76.18%
FY20Y/Y Change
Operating Cash Flow
-80.0K
↓ 113.31%
Investing Cash Flow
-254.4M
↓ 3093.69%
Financing Cash Flow
339.0M
↑ 268966.67%
FY21Y/Y Change
Operating Cash Flow
-84.4M
↑ 105356.25%
Investing Cash Flow
-108.3M
↓ 57.45%
Financing Cash Flow
153.9M
↓ 54.61%
FY22Y/Y Change
Operating Cash Flow
-159.8M
↑ 89.42%
Investing Cash Flow
27.2M
↓ 125.12%
Financing Cash Flow
117.2M
↓ 23.84%
Q4 FY22Q/Q Change
Operating Cash Flow
-38.0M
↓ 18.04%
Investing Cash Flow
55.0M
↓ 187.21%
Financing Cash Flow
-135.0K
↓ 100.12%
Q1 FY23Q/Q Change
Operating Cash Flow
-48.5M
↑ 27.66%
Investing Cash Flow
43.8M
↓ 20.32%
Financing Cash Flow
1.5M
↓ 1197.04%
Q2 FY23Q/Q Change
Operating Cash Flow
-18.5M
↓ 61.88%
Investing Cash Flow
43.8M
↑ 0.0%
Financing Cash Flow
25.0K
↓ 98.31%
Q3 FY23Q/Q Change
Operating Cash Flow
-41.1M
↑ 122.71%
Investing Cash Flow
22.8M
↓ 48.04%
Financing Cash Flow
1.7M
↑ 6716.0%

Technicals Summary

Sell

Neutral

Buy

Nurix Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Nurix Therapeutics Inc
Nurix Therapeutics Inc
2.61%
153.76%
53.58%
-45.89%
-25.51%
Moderna, Inc.
Moderna, Inc.
15.21%
69.71%
-8.11%
-23.64%
414.32%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.36%
17.89%
28.96%
93.09%
194.82%
Novo Nordisk A/s
Novo Nordisk A/s
-0.13%
25.09%
51.14%
233.74%
425.88%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
1.49%
8.83%
19.22%
92.69%
142.73%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Nurix Therapeutics Inc
Nurix Therapeutics Inc
NA
NA
NA
-2.91
-0.65
-0.29
NA
3.43
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.04
26.04
1.46
45.0
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
47.43
47.43
2.4
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Nurix Therapeutics Inc
Nurix Therapeutics Inc
Buy
$754.8M
-25.51%
NA
-178.93%
Moderna, Inc.
Moderna, Inc.
Buy
$41.7B
414.32%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.5B
194.82%
26.04
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$562.8B
425.88%
47.43
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.6B
142.73%
28.81
36.68%

Institutional Holdings

  • BlackRock Inc

    9.50%

  • Baker Bros Advisors LP

    7.94%

  • ARK Investment Management LLC

    6.53%

  • Morgan Stanley - Brokerage Accounts

    6.41%

  • Deep Track Capital, LP

    6.13%

  • Redmile Group, LLC

    5.83%

Corporate Announcements

  • Nurix Therapeutics Inc Earnings

    Nurix Therapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

nurix is a science-focused company that is committed to bringing novel, first-in-class therapies to patients. nurix is a leader in discovering a new class of drugs that work by modulating e3 ubiquitin ligases within the ubiquitin proteasome system (ups). the ups is a regulatory network that controls protein stabilization and degradation – a function vital to the healthy life of a cell – offering therapeutic opportunities in multiple disease areas. nurix’s scientific team has established an innovative drug discovery platform to identify selective inhibitors or activators of the ups, enabling the development of novel therapeutics that can restore normal cellular homeostasis. nurix was founded by internationally recognized experts in the ups field and received its initial funding from leading life science investors, third rock ventures and the column group. in 2015, nurix entered into a multi-year strategic collaboration with celgene to discover and develop next-generation therapies targe

Organization
Nurix Therapeutics Inc
Employees
284
CEO
Dr. Arthur T. Sands M.D., Ph.D.
Industry
Health Technology

Discover More

FAQs